Cidara Therapeutics to Present at the 18th Annual Needham Healthcare Conference
Cidara Therapeutics, Inc. (CDTX)
Last cidara therapeutics, inc. earnings: 3/4 05:55 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cidara.com
Company Research
Source: GlobeNewswire
SAN DIEGO, April 03, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein, Ph.D., president and chief executive officer of Cidara, is scheduled to present at the 18th Annual Needham Healthcare Conference on Tuesday, April 9, 2019, at 11:20 a.m. EDT (8:20 a.m. PDT) in New York City. A live audio webcast and replay of the presentation will be available in the Investors section on the company’s website at www.cidara.com. About Cidara Therapeutics Cidara is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. Cidara is currently advancing its novel echinocandin antifungal, rezafungin acetate, in a Phase 3 clinical trial, for the treatment of candidemia and invasive candidiasis and continue
Show less
Read more
Impact Snapshot
Event Time:
CDTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CDTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CDTX alerts
High impacting Cidara Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CDTX
News
- Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline [Yahoo! Finance]Yahoo! Finance
- Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million [Yahoo! Finance]Yahoo! Finance
- Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 MillionGlobeNewswire
- Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC PipelineGlobeNewswire
- Cidara Therapeutics, Inc. (NASDAQ: CDTX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
CDTX
Earnings
- 11/2/23 - Beat
CDTX
Sec Filings
- 4/24/24 - Form 8-K
- 4/24/24 - Form 8-K
- 4/23/24 - Form S-8
- CDTX's page on the SEC website